此举旨在加强高管团队对早期临床开发的关注，并深化与客户的医疗和科学合作北卡罗来纳州达勒姆, Feb. 18, 2026 (GLOBE NEWSWIRE) -- 全球领先的合同研究组织 (CRO) Fortrea (Nasdaq: FTRE)（以下简称“公司”）今日宣布扩充其高管团队。此前兼任 Fortrea 首席医疗官 (CMO) 和临床药理服务 (CPS) 总裁的 Oren Cohen 医学博士，现专注于其 CMO 职责，主要负责 Fortrea 所有业务的医疗战略、科学领导、伦理和治理监督。Scott Dove 博士加入 Fortrea，担任临床药学服务总裁，负责 Fortrea 在其全球临床研究机构网络中的早期临床开发解决方案。Cohen 和 Dove 均是 Fortrea 的执行委员会成员。 首席执行官 Anshul Thakral 表示：“Scott 加入 Fortrea 团队，同时 Oren 完全专注于开发过程中的医学与科学事务，这对客户而言是一项双赢举措。Oren 将与我们在临床开发各阶段的业务负责人紧密协作，深化其与客户的关系。他更早地参与科学研讨，与公司医师及治疗领域领导者密切协作，共同应对 ...

Adds to executive focus on early clinical development and deepens medical and scientific partnership with clientsDURHAM, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced it has expanded its executive team. Oren Cohen, MD who previously served as both Fortrea’s chief medical officer (CMO) and president of Clinical Pharmacology Services (CPS) is now dedicated to his CMO responsibilities, namely medical strate ...

Core Viewpoint - The article compares Fortrea Holdings Inc. (FTRE) and Prothena (PRTA) to determine which stock is more attractive to value investors [1] Group 1: Zacks Rank and Earnings Outlook - Fortrea Holdings Inc. has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while Prothena has a Zacks Rank of 3 (Hold) [3] - The Zacks Rank system emphasizes companies with positive earnings estimate revisions, suggesting that FTRE is likely experiencing a more favorable earnings outlook [3] Group 2: Valuation Metrics - FTRE has a forward P/E ratio of 13.51, significantly lower than PRTA's forward P/E of 43.81 [5] - FTRE's PEG ratio is 0.30, indicating a more attractive valuation compared to PRTA's PEG ratio of 1.87 [5] - FTRE's P/B ratio is 1.61, while PRTA's P/B ratio is slightly higher at 1.62, contributing to FTRE's superior valuation metrics [6] Group 3: Value Grades - FTRE has a Value grade of A, whereas PRTA has a Value grade of F, highlighting FTRE's stronger position in terms of value investment criteria [6] - The combination of Zacks Rank and Style Scores indicates that FTRE is the more favorable option for value investors at this time [6]

Group 1 - Curreen Capital reported a return of 10.5% in Q4 2025 and 30.97% for the full year, focusing on "ugly ducklings" that are well-managed and attractively priced [1] - The firm's top five holdings contributed significantly to its performance, with Fortrea Holdings Inc. being a key position [1] - Fortrea Holdings Inc. (NASDAQ:FTRE) is a contract research organization with a market capitalization of $1.553 billion, closing at $16.81 per share on January 30, 2026 [2] Group 2 - Fortrea Holdings Inc. had a one-month return of 1.14% and a 52-week gain of 7.28% [2] - Curreen Capital's investment strategy includes identifying "Crazy Cheap" stocks, where Fortrea is classified due to its significant price drop relative to its downside valuation [3] - Fortrea Holdings Inc. was held by 37 hedge fund portfolios at the end of Q3, a slight decrease from 38 in the previous quarter [4]

Group 1 - Fortrea will release its fourth quarter and full year 2025 financial results on February 26, 2026, before the market opens [1] - A conference call will be held at 8:00 am ET on the same day to review the financial results and conduct a Q&A session [1] - Participants can register for the earnings call on the Fortrea Investor Relations website and should join at least 10 minutes early to avoid delays [2] Group 2 - Fortrea is a leading global provider of clinical development solutions to the life sciences industry, partnering with biopharmaceutical, biotechnology, medical device, and diagnostic companies [3] - The company offers phase I-IV clinical trial management, clinical pharmacology, and consulting services, leveraging over 30 years of experience across more than 20 therapeutic areas [3] - Fortrea operates in about 100 countries, providing focused and agile solutions to its customers globally [3]

Core Viewpoint - Fortrea Holdings Inc. (FTRE) is currently viewed as a more attractive option for value investors compared to Acadia Pharmaceuticals (ACAD) based on earnings outlook and valuation metrics [3][7]. Valuation Metrics - FTRE has a forward P/E ratio of 22.52, while ACAD has a forward P/E of 35.71, indicating FTRE is potentially undervalued [5]. - The PEG ratio for FTRE is 0.50, suggesting a favorable growth outlook compared to ACAD's PEG ratio of 6.42, which indicates a less attractive growth valuation [5]. - FTRE's P/B ratio stands at 2.68, compared to ACAD's P/B of 4.83, further supporting FTRE's valuation advantage [6]. Earnings Outlook - FTRE has shown a stronger improvement in its earnings outlook compared to ACAD, contributing to its higher Zacks Rank of 2 (Buy) versus ACAD's 3 (Hold) [3][7].

Core Viewpoint - Kahn Swick & Foti, LLC has initiated an investigation into Fortrea Holdings, Inc. following disappointing financial results and ongoing legal issues related to securities class action lawsuits [1][2][3]. Company Overview - Fortrea Holdings, Inc. was spun off from Labcorp Holdings Inc. in June 2023, becoming a standalone publicly traded company [2]. - The company entered into transition services agreements with Labcorp, agreeing to pay for certain transitional services over a specified period [2]. Financial Performance - On March 3, 2025, Fortrea announced disappointing Q4 and full year 2024 financial results, missing previously announced guidance for revenue and adjusted EBITDA [2]. - The company indicated that pre-spin projects are generating less revenue and profitability than expected for 2025, and post-spin work is not progressing quickly enough to offset the pre-spin contract economics [2]. Legal Issues - Following the financial disclosures, Fortrea and certain executives were sued in a securities class action lawsuit for failing to disclose material information, which is still ongoing [2][3]. - KSF's investigation is focused on potential breaches of fiduciary duties by Fortrea's officers and/or directors, as well as possible violations of state or federal laws [3].

Group 1 - Fortrea Holdings Inc. (NASDAQ:FTRE) is considered one of the best young stocks to buy and hold for three years, with recent price target adjustments from Mizuho and Truist indicating positive market sentiment [1][2][3] - Mizuho raised its price target on Fortrea to $15 from $13 while maintaining a Neutral rating, citing a sequential slowdown in healthcare utilization despite easier comparisons from the previous year [1] - Truist upgraded Fortrea from Hold to Buy, setting a new price target of $22, based on enhanced operational performance, emerging commercial strength, and improved profit margins under new leadership [2] - Evercore ISI upgraded Fortrea from In Line to Outperform, significantly raising its price target to $25 from $14, highlighting an accelerating biopharma cycle and improved execution as key drivers [3] Group 2 - Fortrea Holdings Inc. operates as a contract research organization, providing biopharmaceutical product and medical device development solutions to pharmaceutical, biotech, and medical device customers globally [4]

Core Viewpoint - Momentum investing focuses on "buying high and selling higher" rather than the traditional "buying low and selling high" approach, aiming for quicker profits [1] Group 1: Momentum Investing Characteristics - Fast-moving trending stocks can be difficult to enter at the right time, as they may lose momentum if future growth does not justify their high valuations [2] - Investing in bargain stocks that have recently shown price momentum can be a safer strategy, with tools like the Zacks Momentum Style Score aiding in identifying such stocks [3] Group 2: Fortrea Holdings Inc. (FTRE) Analysis - Fortrea Holdings Inc. (FTRE) has shown a four-week price change of 8.6%, indicating growing investor interest [4] - FTRE has gained 67.2% over the past 12 weeks, demonstrating its ability to deliver positive returns over a longer timeframe [5] - The stock has a beta of 1.59, suggesting it moves 59% higher than the market in either direction, indicating fast-paced momentum [5] - FTRE has a Momentum Score of A, suggesting it is an opportune time to invest in the stock [6] - The stock has a Zacks Rank 2 (Buy) due to upward revisions in earnings estimates, which typically attract more investors [7] - FTRE is trading at a Price-to-Sales ratio of 0.58, indicating it is reasonably valued at 58 cents for each dollar of sales [7] Group 3: Additional Investment Opportunities - Besides FTRE, there are other stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen, which may also present investment opportunities [8] - Investors can explore over 45 Zacks Premium Screens tailored to different investing styles to identify potential winning stocks [9]

Company Overview - Fortrea Holdings is a leading global contract research organization focused on advancing clinical development and providing innovative solutions to accelerate the transition from molecule to medicine [1] - The company was established in 2023 after spinning out from Labcorp, with its roots tracing back to Covance, which was acquired by Labcorp in 2015 [2] Leadership Presentation - The presentation at the 44th JPMorgan Healthcare Conference was led by CEO Anshul Thakral, with CFO Jill McConnell assisting during the Q&A session [1] - The conference serves as a platform for the company to engage with stakeholders and kickstart the year positively [2]